Cited by 2,833Heart Failure Treatment and ManagementHeart rate and cardiovascular healthCardiovascular Function and Risk Factors

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Open access

Cohn, Jay N., Johnson, Gary, Ziesche, Susan, Cobb, Frederick, Francis, Gary, Tristani, Felix, Smith, Raphael, Dunkman, W. Bruce, Loeb, Henry, Wong, Maylene, Bhat, Geetha, Goldman, Steven, Fletcher, Ross D., Doherty, James, Hughes, C. Vincent, Carson, Peter, Cintron, Guillermo, Shabetai, Ralph, Haakenson, Clair·1991·New England Journal of Medicine

DOI 10.1056/nejm199108013250502

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. RESULTS: Mortality after two years was significantly lower in the enalapril arm (18 percent) than in the hydralazine-isosorbide dinitrate arm (25 percent) (P = 0.016; reduction in mortality, 28.0 percent), and overall mortality tended to be lower (P = 0.08). The lower mortality in the enalapril arm was attributable to a reduction in the incidence of sudden death, and this beneficial effect was more prominent in patients with less severe symptoms (New York Heart Association class I or II). In contrast, body oxygen consumption at peak exercise was increased only by hydralazine-isosorbide dinitrate treatment (P less than 0.05), and left ventricular ejection fraction, which increased with both regimens during the 2 years after randomization, increased more (P less than 0.05) during the first 13 weeks in the hydralazine-isosorbide dinitrate group. CONCLUSIONS: The similar two-year mortality in the hydralazine-isosorbide dinitrate arms in our previous Vasodilator-Heart Failure Trial (26 percent) and in the present trial (25 percent), as compared with that in the placebo arm in the previous trial, (34 percent) and the further survival benefit with enalapril in the present trial (18 percent) strengthen the conclusion that vasodilator therapy should be included in the standard treatment for heart failure. The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199108013250502

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citation
A placebo-controlled trial of captopril in refractory chronic congestive heart failure
Captopril Multicenter Research Group (1983) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(83)80316-7 · Cited by 588
Vasodilator Therapy of Cardiac Failure
Cohn, J. N., & Franciosa, J. A. (1977) · New England Journal of Medicine · doi:10.1056/nejm197707072970105 · Cited by 483
Self-citation
The role of vasodilator therapy in heart failure
Chatterjee, K., & Parmley, W. W. (1977) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(77)90006-8 · Cited by 315
Vasodilator Therapy for Heart Failure
Cohn, J. N. (1973) · Circulation · doi:10.1161/01.cir.48.1.5 · Cited by 293
Self-citation
Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure.
Leier, C. V., Huss, P., Magorien, R. D., & Unverferth, D. V. (1983) · Circulation · doi:10.1161/01.cir.67.4.817 · Cited by 289

Show all 19 references

Research works printed but not linked: 1

Cohn, 1987, Circulation, 76, IV–443

Sorted by citations

Items 901–1,000 of 1,000

Angiotensin Converting Enzyme (ACE) Inhibitors and Heart Failure
Andersson, F., Cline, C. M. J., Rydén‐Bergsten, T., & Erhardt, L. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915060-00002 · Cited by 29
Secondary prevention of myocardial infarction: Role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors
Frishman, W. H., & Cheng, A. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70393-5 · Cited by 29
Role of the Renin-Angiotensin System in Cardiovascular Disease
Cohn, J. N. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6230-3 · Cited by 29
Self-citation
Use of Medical Resources and Quality of Life of Patients with Chronic Heart Failure: A Prospective Survey in a Large Italian Community Hospital
Albanese, M. C., Plewka, M., Gregori, D., Fresco, C., Avon, G., Caliandro, D., Grassi, L., Rossi, P. G., Udina, P., Bulfoni, A., et al. (1999) · European Journal of Heart Failure · doi:10.1016/s1388-9842(99)00034-3 · Cited by 29
Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera
Packer, M. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.02.012 · Cited by 28
Pulmonary artery denervation using catheter-based ultrasonic energy
Rothman, A. M. K., Jonas, M., Castel, D., Tzafriri, A. R., Traxler, H., Shav, D., Leon, M. B., Ben‐Yehuda, O., & Rubin, L. J. (2019) · EuroIntervention · doi:10.4244/eij-d-18-01082 · Cited by 28
NHG-Standaard Hartfalen
Hoes, A. W., Voors, A., Rutten, F. H., van Lieshout, J., Janssen, P. G. H., & Walma, E. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8279-8_24 · Cited by 28
Defining the Role of Calcium Channel Antagonists in Heart Failure Due to Systolic Dysfunction
Mah, I., Chassany, O., Grenard, A.-S., Caulin, C., & Bergmann, J. (2003) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200303010-00004 · Cited by 28
The Food and Drug Administration and pragmatic clinical trials of marketed medical products
Anderson, M. L., Griffin, J. C. M., Goldkind, S. F., Zeitler, E. P., Wing, L., Al‐Khatib, S. M., & Sherman, R. E. (2015) · Clinical Trials · doi:10.1177/1740774515597700 · Cited by 28
Pharmacotherapy of congestive heart failure
van Zwieten, P. A. (1994) · Pharmacy World & Science · doi:10.1007/bf02178563 · Cited by 28
Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: The losartan heart failure ELITE quality of life substudy
Cowley, A. J., Wiens, B. L., Segal, R., Rich, M. W., Santanello, N. C., Dasbach, E. J., & Pitt, B. (2000) · Quality of Life Research · doi:10.1023/a:1008948930206 · Cited by 28
Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction
Thadani, U., & Ripley, T. L. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.4.385 · Cited by 28
Novel Pathophysiological Insight and Treatment Strategies for Heart Failure-Lessons From Mice and Patients-
Tsutsui, H. (2004) · Circulation Journal · doi:10.1253/circj.68.1095 · Cited by 28
Congestive Heart Failure
Chatterjee, K. (2002) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200202010-00001 · Cited by 28
Pacing for Heart Failure: Selection of Patients, Techniques and Benefits
Auricchio, A., Klein, H., & Spinelli, J. (1999) · European Journal of Heart Failure · doi:10.1016/s1388-9842(99)00037-9 · Cited by 28
ACE Inhibitors in Heart Failure: Prospects and Limitations
Pitt, B. (1997) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007795915009 · Cited by 28
Angiotensin-converting enzyme inhibitors after myocardial infarction: Indications and timing
Ball, S. G., Hall, A. S., & Murray, G. D. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00102-a · Cited by 28
Treatment of chronic mitral regurgitation
Cooper, H. A., & Gersh, B. J. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70056-0 · Cited by 28
Gender differences and practice implications of risk factors for frequent hospitalization for heart failure in an urban center serving predominantly African-American patients
Ofili, E., Mayberry, R., Alema‐Mensah, E., Saleem, S., Hamirani, K., Jones, C., Salih, S., Lankford, B., Oduwole, A. M., & Igho-Pemu, P. E. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00099-5 · Cited by 28
Long-term follow up of patients with implantable cardioverter-defibrillators and mild, moderate, or severe impairment of left ventricular function.
Trappe, H.-J., WENZLAFF, P., PFITZNER, P., & Fieguth, H. (1997) · Heart · doi:10.1136/hrt.78.3.243 · Cited by 28
Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction
Pitt, B. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90482-g · Cited by 28
Implantable Cardioverter Defibrillator: Effect on Survival
Schlepper, M., Neuzner, J., & PITSCHNER, H. F. (1995) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1995.tb02567.x · Cited by 28
Foundation/American Heart Association Task Force on Practice Guidelines Heart Failure in Adults. A Report of the American College of Cardiology Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of
Ganiats, T. G., Konstam, M. A., MANCINI, D. M., Abraham, W. T., Casey, D. E., Feldman, A. M., & Ma, G. S. (2009) · Cited by 27
Kicking the Tyres of a Heart Failure Trial: Physician Response to the Approval of Sacubitril/valsartan in the USA
Packer, M. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.623 · Cited by 27
Aliskiren Alone or in Combination with Enalapril vs. Enalapril Among Patients with Chronic Heart Failure with and without Diabetes: A Subgroup Analysis from the ATMOSPHERE Trial
Kristensen, S. L., Mogensen, U. M., Tarnesby, G., Gimpelewicz, C. R., Ali, M. A., Shao, Q., Chiang, Y., Jhund, P. S., Abraham, W. T., Dickstein, K., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.896 · Cited by 27
Congestive heart failure in Indians: How do we improve diagnosis & management?
Sreenivas Reddy, S., Bahl, A., & Talwar, K. K. (2010) · The Indian Journal of Medical Research · doi:10.4103/ijmr.2010_132_05_549 · Cited by 27
Relationship between late ventricular potentials and myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with dilated cardiomyopathy with mild to moderate heart failure: results of a prospective study of sudden death events
Kasama, S., Toyama, T., Kaneko, Y., Iwasaki, T., Sumino, H., Kumakura, H., Minami, K., Ichikawa, S., Matsumoto, N., Sato, Y., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2092-1 · Cited by 27
Cholinergic stimulation with pyridostigmine, hemodynamic and echocardiographic analysis in healthy subjects
Pontes, P. V., Bastos, B. G., Filho, L. J. M. R., Mesquita, E. T., & da Nóbrega, A. C. L. (1999) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x1999000300003 · Cited by 27
Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin–angiotensin system
Guo, X., Saini, H. K., Wang, J., Gupta, S. K., Goyal, R. K., & Dhalla, N. S. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.4.717 · Cited by 27
Impact of specialist care in patients with newly diagnosed heart failure: A randomised controlled study
Rao, A., & Walsh, J. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.03.010 · Cited by 27
Renal response to captopril reflects state of local renin system in healthy humans
Fisher, N. D. L., Price, D. A., Litchfield, W. R., Williams, G. H., & Hollenberg, N. K. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00579.x · Cited by 27
Heart Failure: why and how to Define it?
Purcell, I. F., & Poole-Wilson, P. A. (1999) · European Journal of Heart Failure · doi:10.1016/s1388-9842(98)00009-9 · Cited by 27
Sudden cardiac death
Sra, J. S., Dhala, A. A., Blanck, Z., Deshpande, S., Cooley, R., & Akhtar, M. (1999) · Current Problems in Cardiology · doi:10.1016/s0146-2806(99)90004-x · Cited by 27
Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes
Hockensmith, M. L., Estacio, R. O., Mehler, P. S., Havranek, E. P., Ecder, T., Lundgren, R. A., & Schrier, R. W. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2003.09.003 · Cited by 27
Predictors of sudden death and death from pump failure in congestive heart failure are different. Analysis of 24 h Holter monitoring, clinical variables, blood chemistry, exercise test and radionuclide angiography
Madsen, B. K., Rasmussen, V., & Hansen, J. F. (1997) · International Journal of Cardiology · doi:10.1016/s0167-5273(96)02853-7 · Cited by 27
Phospholipid-mediated signaling systems as novel targets for treatment of heart diseaseThis paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.
Tappia, P. S. (2007) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y06-098 · Cited by 27
CONGESTIVE HEART FAILURE IN OLDER PERSONS
Aronow, W. S., Tresch, D. D., & Aronow, W. S. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb03780.x · Cited by 27
The management of congestive heart failure
McAlister, F. A., & Teo, K. K. (1997) · Postgraduate Medical Journal · doi:10.1136/pgmj.73.858.194 · Cited by 27
What Can We Expect from Prophylactic Implantable Defibrillators?
Wilber, D. J., Kall, J. G., & Kopp, D. E. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00479-7 · Cited by 27
Blood pressure control, microalbuminuria and cardiovascular risk in Type 2 diabetes mellitus
Marshall, S. M. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00045.x · Cited by 27
Tolerance: An Historical Overview
Abrams, J., Elkayam, U., Thadani, U., & Fung, H. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00992-2 · Cited by 27
Calcium channel blockers in cardiac failure
Mahon, N., & McKenna, W. J. (1998) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(98)80055-8 · Cited by 27
Advances in the Treatment of Congestive Heart Failure: New Approaches for an Old Disease
Skrabal, M. Z., Stading, J. A., Behmer-Miller, K. A., & Hilleman, D. E. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.9.787.35195 · Cited by 27
SAFE AND EFFECTIVE MANAGEMENT OF HYPERTENSION WITH FIXED‐DOSE COMBINATION THERAPY: FOCUS ON LOSARTAN PLUS HYDROCHLOROTHIAZIDE
Benedict, C. (2000) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2000.tb11842.x · Cited by 27
Heart Failure Due to Reduced Ejection Fraction: Medical Management.
Chavey, W. E., Hogikyan, R. V., Harrison, R. V., & Nicklas, J. M. (2017) · PubMed · Cited by 26
Hypertension in ethnic groups: epidemiological and clinical perspectives
Dwivedi, G., & Beevers, D. G. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.88 · Cited by 26
Fosinopril
Davis, R., Coukell, A. J., & McTavish, D. (1997) · Drugs · doi:10.2165/00003495-199754010-00012 · Cited by 26
The prognostic implications of outpatient diuretic dose in heart failure
Harjai, K. J., Dinshaw, H. K., Núñez, E., Shah, M. P., Thompson, H. W., Turgut, T., & Ventura, H. O. (1999) · International Journal of Cardiology · doi:10.1016/s0167-5273(99)00129-1 · Cited by 26
Heart failure in African Americans: pathophysiology and treatment*1
Yancy, C. W. (2003) · Journal of Cardiac Failure · doi:10.1054/s1071-9164(03)00590-6 · Cited by 26
Nonischemic Heart Failure: Epidemiology, Pathophysiology and Progression of Disease
Follath, F. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199906003-00004 · Cited by 26
Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: A budget impact analysis
Smith, D. G., Cerulli, A., & Frech, F. H. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.014 · Cited by 26
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
Sica, D. A. (2001) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200109000-00008 · Cited by 26
Underutilization of ACE Inhibitors in Heart Failure
Luzier, A. B., & DiTusa, L. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.16.1296.30880 · Cited by 26
Current and novel pharmacologic approaches in advanced heart failure
O’Connor, C. M., Gattis, W. A., & Swedberg, K. B. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70254-6 · Cited by 26
HEART FAILURE
Rich, M. W. (1999) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70060-6 · Cited by 26
Heart failure in the elderly: advances and challenges
Jugdutt, B. I. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.36 · Cited by 26
Uptitration of Renin-Angiotensin System Blocker and Beta-Blocker Therapy in Patients Hospitalized for Heart Failure With Reduced Versus Preserved Left Ventricular Ejection Fractions
Verbrugge, F. H., Duchenne, J., Bertrand, P. B., Dupont, M., Tang, W. H. W., & Müllens, W. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.013 · Cited by 25
Heart Failure in the Elderly
Forman, D. E., & Rich, M. W. (2003) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2003.00798.x · Cited by 25
Pharmacologic Therapy of Chronic Heart Failure
Hamad, E., Mather, P. J., Srinivasan, S., Rubin, S., Whellan, D. J., & Feldman, A. M. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707040-00002 · Cited by 25
Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensinconverting enzyme inhibitors is not beneficial: Results of a placebo-controlled, double-blind study
Dorszewski, A., Gohmann, E. J., DORSZEWSKI, B., Werner, G. S., Kreuzer, H., & Figulla, H. R. (1997) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(97)90040-3 · Cited by 25
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement
Rossano, J. W., Cabrera, A. G., Jefferies, J. L., Naim, M. Y., & Humlicek, T. J. (2016) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000624 · Cited by 25
New therapeutic strategies for heart failure: left ventricular remodeling as a target
Cohn, J. N. (2004) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2004.09.007 · Cited by 25
Self-citation
Genital Herpes Simplex Infections in Patients With the Acquired Immunodeficiency Syndrome
McGrath, B. J., & Newman, C. L. (1994) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1994.tb02850.x · Cited by 25
Utilisation des inhibiteurs calciques dans le traitement de l??insuffisance cardiaque
Gattis, W. A., & Connor, C. M. O. (2000) · Drugs · doi:10.2165/00003495-200059992-00003 · Cited by 25
Health-related quality of life measurement in heart failure: Challenges for the new millennium
Alkaade, S., & Hauptman, P. J. (2001) · Journal of Cardiac Failure · doi:10.1054/jcaf.2001.24664 · Cited by 25
Association between ACE Inhibitors and Acute Pancreatitis in the Elderly
Cheng, R., Mamdani, M., Jackevicius, C. A., & Tu, K. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c270 · Cited by 25
Vasodilators in Heart Failure
Cohn, J. N. (1994) · Drugs · doi:10.2165/00003495-199400474-00008 · Cited by 25
Self-citation
Overview of the Treatment of Heart Failure
Cohn, J. N. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00843-6 · Cited by 25
Self-citation
Sample sizes for event rate equivalence trials using prior information
Gould, A. L. (1993) · Statistics in Medicine · doi:10.1002/sim.4780122105 · Cited by 25
Is There a Role for Endothelin in the Natural History of Heart Failure?
Cohn, J. N. (1996) · Circulation · doi:10.1161/01.cir.94.4.604 · Cited by 25
Self-citation
2023 Consensus of Taiwan Society of Cardiology on the Pharmacological Treatment of Chronic Heart Failure.
Chiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 24
Cardiac Remodelling in the Era of the Recommended Four Pillars Heart Failure Medical Therapy
Colombo, G., Biering‐Sørensen, T., Ferreira, J. P., Lombardi, C., Bonelli, A., Garascia, A., Metra, M., & Inciardi, R. M. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15095 · Cited by 24
Pathophysiology and Clinical Use of Agents with Vasodilator Properties in Acute Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Chioncel, O. D., Mebazaa, A., Farmakis, D. T., Abdelhamid, M., Lund, L. H., Harjola, V., Anker, S. D., Filippatos, G., Gal, T. B., Damman, K., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3673 · Cited by 26
Contemporary Medical Management of Systolic Heart Failure
Nair, A. P., Timoh, T., & Fuster, V. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1424 · Cited by 24
Unbelievable Folly of Clinical Trials in Heart Failure
Packer, M. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.002837 · Cited by 24
ACE Inhibitors in Heart Failure
Demers, C., Mody, A., Teo, K. K., & McKelvie, R. S. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505060-00002 · Cited by 24
Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?
Bielecka-Dabrowa, A. M., Godoy, B., Schefold, J. C., Koziolek, M. J., Banach, M., & von Haehling, S. (2018) · Current Heart Failure Reports · doi:10.1007/s11897-018-0397-5 · Cited by 24
Contemporary Management of Heart Failure in the Elderly
Osmanska, J., & Jhund, P. S. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0625-4 · Cited by 26
Czech and Slovak spirapril intervention study (CASSIS)
Widimsky, J., Jr., Uhlír, O., Kremer, H.-J., & Jerie, P. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00192366 · Cited by 24
Safety of Angiotensin-Converting Enzyme Inhibitors in Patients with Bilateral Renal Artery Stenosis Following Successful Renal Artery Stent Revascularization
Khosla, S., Ahmed, A., Siddiqui, M., Trivedi, A., Benatar, D., Salem, Y., Elbzour, M., Vidyarthi, V., & Lubell, D. (2006) · American Journal of Therapeutics · doi:10.1097/00045391-200607000-00005 · Cited by 24
Inhibiting the renin–angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials
Tokmakova, M. P., & Solomon, S. D. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000231394.79609.24 · Cited by 24
Peak VO2 is More Potent Than B-Type Natriuretic Peptide as a Prognostic Parameter in Cardiac Patients
Kubozono, T., Itoh, H., Oikawa, K., Tajima, A., Maeda, T., Aizawa, T., Iinuma, H., Tokuda, Y., Ohashi, Y., & Fu, L.-T. (2007) · Circulation Journal · doi:10.1253/circj.72.575 · Cited by 24
Comparing methods to identify general internal medicine clinic patients with chronic heart failure
Udris, E. M., Au, D. H., McDonell, M. B., Chen, L., Martin, D. C., Tierney, W. M., & Fihn, S. D. (2001) · American Heart Journal · doi:10.1067/mhj.2001.119130 · Cited by 24
Oral Nitrates: More Than Symptomatic Therapy in Coronary Artery Disease?
Thadani, U. (1997) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007750706831 · Cited by 24
Effects of the angiotensin‐converting enzyme inhibitor alacepril on exercise capacity and neurohormonal factors in patients with mild‐to‐moderate heart failure
Kinugawa, T., Osaki, S., Kato, M., Oginö, K., Shimoyama, M., Tomikura, Y., Igawa, O., Hisatome, I., & Shigemasa, C. (2002) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2002.03779.x · Cited by 24
Recruitment strategies in the studies of left ventricular dysfunction (SOLVD): Strategies for screening and enrollment in two concurrent but separate trials
Carew, B. D., Ahn, S. A., Boichot, H. D., Dierenfeldt, B. J., Dolan, N., Edens, T. R., Weiner, D. H., & Probstfield, J. L. (1992) · Controlled Clinical Trials · doi:10.1016/0197-2456(92)90035-x · Cited by 24
Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: Results of a placebo-controlled trial
GUNDERSEN, T., Wiklund, I. E., Swedberg, K. B., Amtorp, O., Remes, J., Nilsson, B., & the Ramipril Study Group (1995) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00878091 · Cited by 24
Exercise and Heart Failure
Piña, I. L., & Fitzpatrick, J. T. (1996) · CHEST Journal · doi:10.1378/chest.110.5.1317 · Cited by 24
Management of refractory congestive heart failure
Cody, R. J. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91262-3 · Cited by 24
Brain natriuretic peptide-guided therapy for heart failure
Nicholls, M. G., Lainchbury, J. G., Richards, M., Troughton, R. W., & Yandle, T. G. (2001) · Annals of Medicine · doi:10.3109/07853890108995955 · Cited by 24
Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure
Ramahi, T. M., Longo, M. D., Rohlfs, K., & Sheynberg, N. (2000) · Clinical Cardiology · doi:10.1002/clc.4960231211 · Cited by 24
Cardiomyopathy Trial
THE CARDIOMYOPATHY TRIAL INVESTIGATORS (1993) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1993.tb01628.x · Cited by 24
Left Ventricular Mechanical Dyssynchrony as Assessed by Phase Analysis of ECG‐Gated SPECT Myocardial Perfusion Imaging
Chen, J., Garcia, E. V., Lerakis, S., Henneman, M. M., Bax, J. J., Trimble, M. A., Borges‐Neto, S., Velazquez, E. J., & Iskandrian, A. E. (2008) · Echocardiography · doi:10.1111/j.1540-8175.2008.00782.x · Cited by 23
Neurohormonal control of heart failure
Francis, G. S. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78.s1.13 · Cited by 23
Self-citation
Improving the Quality of Clinical Pharmacy Services: A Process to Identify and Capture High-Value “Quality Actions”
de Lemos, J., Bruchet, N., & Loewen, P. S. (2011) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v64i1.986 · Cited by 23
Update on therapy for heart failure
DiBianco, R. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00265-1 · Cited by 23
Pharmacogenomics and the Challenge of Health Disparities
Lee, S. S. (2009) · Public Health Genomics · doi:10.1159/000189630 · Cited by 24
Gender Differences in Egyptian Patients Hospitalized with Heart Failure: Insights from the European Society of Cardiology Heart Failure Long-Term Registry
Hassanein, M., Abdelhamid, M., Ibrahim, B., Sobhy, M. A., Nasr, G. M., Aboleineen, M. W., Reda, A., Farag, N. M., Elshazly, A., Abdeldayem, T. K., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12347 · Cited by 23
The PTIP-Associated Histone Methyltransferase Complex Prevents Stress-Induced Maladaptive Cardiac Remodeling
Stein, A., Goonewardena, S. N., Jones, T. A., Prusick, P. J., Bazzi, A. A., Belyavskaya, J. M., McCoskey, M. M., & Dandar, R. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127839 · Cited by 23
Cardio-renal anemia syndrome.
Efstratiadis, G., Konstantinou, D. M., Chytas, I., & Vergoulas, G. (2008) · PubMed Central · Cited by 23

Authors: Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., Bhat, G., Goldman, S., Fletcher, R. D., Doherty, J., Hughes, C. V., Carson, P., Cintron, G., Shabetai, R., & Haakenson, C.
Affiliations: University of Minnesota (US)
ORCID: Cohn, Jay N.
Johnson, Gary
Bhat, Geetha
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1991-08
Volume: 325
Issue: 5
Pages: 303-310
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199108013250502
OpenAlex: W2046383587
Cited by: 2,833
References: 19
Citations by year: 2026: 14 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 27 · 2020: 46 · 2019: 39 · 2018: 51 · 2017: 56 · 2016: 69 · 2015: 59 · 2014: 54 · 2013: 61 · 2012: 56
FWCI: 124.25
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords: enalapril, hydralazine, isosorbide dinitrate, chronic congestive heart failure, vasodilator therapy, mortality, sudden death, exercise oxygen consumption, left ventricular ejection fraction, ACE inhibitors, combination therapy, digoxin, diuretics, NYHA functional class
MeSH terms: Adolescent, Adult, Aged, Chronic Disease, Death, Sudden, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Enalapril, Physical Exertion, Heart Failure, Hospitalization, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Norepinephrine, Oxygen Consumption, Patient Compliance, Stroke Volume, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks